From: VIP Regulates the Development & Proliferation of Treg in vivo in spleen
Group 1: Controls (n = 10) | Group 2: VIP KO (n = 5) | Group 3: VIP KO + VIP (n = 5) | p-values for Group Comparisons | ||||||
---|---|---|---|---|---|---|---|---|---|
Median | Min, Max | Median | Min, Max | Median | Min, Max | 1 vs. 2 | 1 vs. 3 | 2 vs. 3 | |
CD4-CD25+ | 29 | 6, 73 | 31 | 19, 429 | 47 | 33, 89 | 0.63 | 0.12 | 0.18 |
CD4-CD25+Helios+ | 1 | 0, 4 | 4 | 0, 164 | 2 | 0, 10 | 0.046 | 0.31 | 0.61 |
CD4-CD25+FoxP3+Helios+ | 4 | 0, 19 | 0 | 0, 0 | 0 | 0, 2 | 0.069 | 0.32 | 0.14 |
CD4+CD25+ (Treg) | 435 | 88, 1383 | 374 | 199, 611 | 380 | 198, 489 | 1.00 | 1.00 | 0.61 |
CD4+CD25+FoxP3+Helios- (Treg induced intrasplenically) | 109 | 8, 359 | 9 | 4, 37 | 150 | 99, 226 | 0.038 | 0.91 | 0.0091* |
CD4+CD25+FoxP3-Helios+ (Treg) | 83 | 0, 270 | 254 | 108, 352 | 96 | 21, 157 | 0.028 | 0.91 | 0.029 |
CD4+CD25+ FoxP3+Helios+ (Treg) | 68 | 2, 251 | 6 | 0, 22 | 82 | 53, 141 | 0.087 | 0.91 | 0.0091* |